Commentary

Going the distance with our patients

Author and Disclosure Information

 

References

Many years ago, I had a patient I’ll call “Hannah,” who was well into her 80s and always came into the office with her daughter. She was a heavy smoker and had hypertension and type 2 diabetes.

At each visit, I would ask her if she still smoked and if she was interested in talking about quitting. At every visit, she would say that she was still smoking and didn’t want to quit. My response was always something along the lines of: “When you’re ready, we can talk more. But I think it is the most important thing you can do to improve your health.” From there, we would discuss any concerns she or her daughter had.

It is our longitudinal relationships with patients that allow us to plant seeds and reap the benefits over time.

A few years shy of her 100th birthday, Hannah told me she had quit smoking. I was amazed and asked her why, after all these years, she’d done it.

“I quit,” she said, “because I was tired of you nagging me, sonny!” And we both had a good laugh about that.

Hannah’s story reminds me that, as family physicians, we often have an impact on our patients in ways we don’t see in the short term. It is our longitudinal relationships with patients that allow us to plant seeds and reap the benefits over time.

It is these relationships that we can draw upon when counseling our patients with type 2 diabetes to address lifestyle issues such as exercise and a healthy diet. In this issue, McMullan et al1 provide us with a rather hopeful review of the evidence in support of lifestyle changes. For our patients with type 2 diabetes, lifestyle changes can decrease A1C levels by 0.5% (with environmental changes related to diet)2 and 0.7% (with moderate aerobic exercise).3 This is comparable to what is reported for the starting doses of most medications.4 In fact, a meta-analysis showed that a low-carbohydrate diet induced remission at 6 months in 32% of patients.5 (Caveat: The result was not controlled for weight loss as a possible confounding factor and an A1C cutoff of 6.5% was used.)

And yet, we often focus more on the various medications we can prescribe, with professional guidelines pointing the way.

Continue to: The National Institute for Health and Care Excellence

Pages

Recommended Reading

Ezetimibe-statin combo lowers liver fat in open-label trial
MDedge Family Medicine
Once-weekly insulin promising in phase 3 trial in type 2 diabetes
MDedge Family Medicine
How to improve diagnosis of HFpEF, common in diabetes
MDedge Family Medicine
Strong link found between enterovirus and type 1 diabetes
MDedge Family Medicine
Balanced fat intake links with less type 2 diabetes
MDedge Family Medicine
Food insecurity a growing problem for many with CVD
MDedge Family Medicine
Newer drugs not cost effective for first-line diabetes therapy
MDedge Family Medicine
Bariatric surgery prompts visceral fat reduction, cardiac changes
MDedge Family Medicine
Dapagliflozin DELIVERs regardless of systolic pressure in HFpEF
MDedge Family Medicine
Maximizing lifestyle changes to manage type 2 diabetes
MDedge Family Medicine